Subcutaneous delivery of biotherapeutics: challenges at the injection site

References

• Jones GB, Collins DS, Harrison MW, et al. Subcutaneous drug delivery: an evolving enterprise. Sci Transl Med. 2017;9:405.
   Web of Science ®Google Scholar
• Evens RP. Pharma success in product development-does biotechnology change the paradigm in product development and attrition. AAPS J. 2016;18(1):281–285.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655–672.
   PubMed Web of Science ®Google Scholar
• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9–14.
   PubMed Web of Science ®Google Scholar
• Viola M, Sequeira J, Seica R, et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release. 2018;286:301–314.
   PubMed Web of Science ®Google Scholar
• Cook IF. Evidence based route of administration of vaccines. Hum Vaccin. 2008;4(1):67–73.
   PubMed Web of Science ®Google Scholar
• Varamini P, Toth I. Recent advances in oral delivery of peptide hormones. Expert Opin Drug Deliv. 2016;13(4):507–522.
   PubMed Web of Science ®Google Scholar
• Vaishya R, Khurana V, Patel S, et al. Long-term delivery of protein therapeutics. Expert Opin Drug Deliv. 2015;12(3):415–440.
   PubMed Web of Science ®Google Scholar
• Turner MR, Balu-Iyer SV. Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. J Pharm Sci. 2018;107(5):1247–1260.
   PubMed Web of Science ®Google Scholar
• Stoner KL, Harder H, Fallowfield LJ, et al. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient. 2015;8(2):145–153.
   Google Scholar
• Pivot X, Gligorov J, Muller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (prefher): an open-label randomised study. Lancet Oncol. 2013;14(10):962–970.
   PubMed Web of Science ®Google Scholar
• Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298–306.
   PubMed Web of Science ®Google Scholar
• Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv. 2005;2(1):29–42.
   PubMedGoogle Scholar
• Stevenson CL, Rhodes CA, Prestrelski SJ. Delivery of peptides and proteins via long acting injections and implants. In: Wright JC, Burgess DJ, editors. Long acting injections and implants. New York: Springer; 2012. Chapter 20, 409–427.
   Google Scholar
• Am F, Sv B-I. Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics. J Pharm Sci. 2015;104(2):301–306.
   PubMed Web of Science ®Google Scholar
• Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following sc administration. AAPS J. 2012;14(3):559–570.
   PubMed Web of Science ®Google Scholar
• McDonald TA, Zepeda ML, Tomlinson MJ, et al. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther. 2010;12(4):461–470.
   PubMedGoogle Scholar
• Mathaes R, Koulov A, Joerg S, et al. Subcutaneous injection volume of biopharmaceuticals-pushing the boundaries. J Pharm Sci. 2016;105(8):2255–2259.
   PubMed Web of Science ®Google Scholar
• Kinnunen HM, Mrsny RJ. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. J Control Release. 2014;182:22–32.
   PubMed Web of Science ®Google Scholar
• Richter WF, Jacobsen B. Subcutaneous absorption of biotherapeutics: knowns and unknowns. Curr Opin Mol Ther. 2014;42(11):1881–1889.
   Google Scholar
• Swartz MA. The physiology of the lymphatic system. Adv Drug Del Rev. 2001;50(1–2):3–20.
   PubMed Web of Science ®Google Scholar
• Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev. 2012 Jul;92(3):1005–1060.
   PubMed Web of Science ®Google Scholar
• Iyer SS, Barr WH, Karnes HT. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm Drug Disp. 2006;27(4):157–170.
   PubMed Web of Science ®Google Scholar
• Leung DH, Kapoor Y, Alleyne C, et al. Development of a convenient in vitro gel diffusion model for predicting the in vivo performance of subcutaneous parenteral formulations of large and small molecules. AAPS Pharmscitech. 2017;18(6):2203–2213.
   PubMed Web of Science ®Google Scholar
• Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(24):4195–4200.
   PubMed Web of Science ®Google Scholar
• Horkay F, Basser PJ, Hecht AM, et al. Chondroitin sulfate in solution: effects of mono- and divalent salts. Macromolecules. 2012;45(6):2882–2890.
   PubMed Web of Science ®Google Scholar
• Collins DS, Kourtis LC, Thyagarajapuram NR, et al. Optimizing the bioavailability of subcutaneously administered biotherapeutics through mechanochemical drivers. Pharm Res. 2017;34(10):2000–2011.
   PubMed Web of Science ®Google Scholar
• Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009;326(5957):1216–1219.
   PubMed Web of Science ®Google Scholar
• Gagnon-Auger M, Du Souich P, Jp B, et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010;33(12):2502–2507.
   PubMed Web of Science ®Google Scholar
• McDowell A, Medlicott NJ. Anatomy and physiology of the injection site: implications for extended release parenteral systems. In: Wright JC, Burgess DJ, editors. Long acting injections and implants. New York: Springer; 2012. chapter 4, 57–71.
   Google Scholar
• Jockel JPL, Roebrock P, Shergold OA. Insulin depot formation in subcutaneoue tissue. J Diabetes Sci Technol. 2013;7(1):227–237.
   PubMedGoogle Scholar
• Fung LK, Saltzman WM. Polymeric implants for cancer chemotherapy. Adv Drug Del Rev. 1997;26(2–3):209–230.
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Poh MZ, Insin N, et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J. 2010;99(5):1342–1349.
   PubMed Web of Science ®Google Scholar
• Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009;17(2):153–162.
   PubMed Web of Science ®Google Scholar
• Laurent TC, Ogston AG. The interaction between polysaccharides and other macromolecules. 4. The osmotic pressure of mixtures of serum albumin and hyaluronic acid. Biochem J. 1963;89(2):249–253.
   PubMed Web of Science ®Google Scholar
• Mach H, Gregory SM, Mackiewicz A, et al. Electrostatic interactions of monoclonal antibodies with subcutaneous tissue. Ther Deliv. 2011;2(6):727–736.
   PubMedGoogle Scholar
• Jarvelainen H, Sainio A, Koulu M, et al. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev. 2009;61(2):198–223.
   PubMed Web of Science ®Google Scholar
• Pomin VH, Mulloy B. Glycosaminoglycans and Proteoglycans. Pharmaceuticals. 2018;11(1):27.
   Web of Science ®Google Scholar
• Wang W. Advanced protein formulations. Protein Sci. 2015;24(7):1031–1039.
   PubMed Web of Science ®Google Scholar
• Warne NW. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. Eur J Pharm Biopharm. 2011;78(2):208–212.
   PubMed Web of Science ®Google Scholar
• Kinnunen HM, Sharma V, Contreras-Rojas LR, et al. A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components. J Control Release. 2015;214:94–102.
   PubMed Web of Science ®Google Scholar
• Rayaprolu BM, Strawser JJ, Anyarambhatla G. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics. Drug Dev Ind Pharm. 2018;44(10):1565–1571.
   PubMed Web of Science ®Google Scholar
• Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009;20(6):708–714.
   PubMed Web of Science ®Google Scholar
• Mj F. Diabetes treatment, Part 3: insulin and incretins. Clin Diabetes. 2008;26(1):35–39.
   Google Scholar
• Lo Nostro P, Ninham BW. Hofmeister phenomena: an update on ion specificity in biology. Chem Rev. 2012;112(4):2286–2322.
   PubMed Web of Science ®Google Scholar
• Hagstrom E, Arner P, Ungerstedt U, et al. Subcutaneous adipose tissue: a source of lactate production after glucose ingestion in humans. Am J Physiol. 1990;258(5):E888–E893.
   PubMedGoogle Scholar
• Kidman G, Park H, Northrop DB. Pressure stability of proteins at their isoelectric points. Protein Pept Lett. 2004;11(6):543–546.
   PubMed Web of Science ®Google Scholar
• Talley K, Alexov E. On the pH-optimum of activity and stability of proteins. Proteins Struct Funct Bioinf. 2010;78(12):2699–2706.
   PubMed Web of Science ®Google Scholar
• Kovalainen M, Monkare J, Riikonen J, et al. Novel delivery systems for improving the clinical use of peptides. Pharmacol Rev. 2015;67(3):541–561.
   PubMed Web of Science ®Google Scholar
• Singh SK, Mahler H-C, Hartman C, et al. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants? J Pharm Sci. 2018;107(11):2735–2741.
   PubMed Web of Science ®Google Scholar
• Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. Biodrugs. 2018;32(5):425–440.
   PubMed Web of Science ®Google Scholar
• Larsen C, Larsen SW, Jensen H, et al. Role of in vitro release models in formulation development and quality control of parenteral depots. Expert Opin Drug Deliv. 2009;6(12):1283–1295.
   PubMed Web of Science ®Google Scholar
• McLennan DN, Porter CJH, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol. 2005;2(1):89–96.
   PubMedGoogle Scholar
• Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy. Adv Drug Del Rev. 2016;103:144–156.
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Kaminskas LM, Porter CJH. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015;14(11):781–803.
   PubMed Web of Science ®Google Scholar
• Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21–39.
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokin. 2010;49(10):633–659.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
   PubMed Web of Science ®Google Scholar
• Cowman M, Schmidt T, Raghavan P, et al. Viscoelastic properties of hyaluronan in physiological conditions [version 1; referees: 2 approved]. F1000Res. 2015;4:622.
   PubMedGoogle Scholar
• Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427–440.
   PubMed Web of Science ®Google Scholar
• Kang DW, Oh DA, Fu GY, et al. Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein. J Pharmacol Toxicol Methods. 2013;67(3):140–147.
   PubMed Web of Science ®Google Scholar
• Bown HK, Bonn C, Yohe S, et al. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies. J Control Release. 2018;273:13–20.
   PubMed Web of Science ®Google Scholar